Mesothelioma  >>  Opdivo (nivolumab) 
Welcome,         Profile    Billing    Logout  

29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Opdivo (nivolumab) / BMS
ACTRN12620001199909: DREAM3R: A phase 3 trial of durvalumab with chemotherapy as first line treatment in mesothelioma

Recruiting
3
480
 
University of Sydney, AstraZeneca Pty Ltd
Pleural Mesothelioma (PM)
 
 
CheckMate743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
CONFIRM, NCT03063450 / 2016-003111-35: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Active, not recruiting
3
332
Europe
Nivolumab, Opdivo, Placebo
University of Southampton, Bristol-Myers Squibb
Mesothelioma
02/23
02/23
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
eVOLVE-Meso, NCT06097728: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Volrustomig, MEDI5752, Pemetrexed, Alimta, Carboplatin, Paraplatin, Cisplatin, Platinol, Nivolumab, Opdivo, Ipilimumab, Yervoy
AstraZeneca
Unresectable Pleural Mesothelioma
03/27
03/28
2019-002466-13: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Not yet recruiting
2
92
Europe
Nivolumab, Concentrate for solution for infusion, Opdivo
Institut für Klinische Krebsforschung IKF GmbH, Bristol-Myers Squibb GmbH & Co. KGaA
Malignant Pleural Mesothelioma, Malignant Pleural Mesothelioma, Diseases [C] - Cancer [C04]
 
 
2019-003003-35: IMPALA IMPALA

Not yet recruiting
2
20
Europe
Nivolumab, BMS936558, Solution for injection, Nivolumab solution for injection
CHU de LILLE, Bristol-Myers Squibb
Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies in patients with malignant pleural mesothelioma Etude pilote de faisabilité d’un traitement innovant combinat la thérapie photodynamique intrapleurale et une immunothérapie adjuvante par Nivolumab chez des patients porteurs d’un mésothéliome pleural malin, Malignant Pleural Mesothelioma Mésothéliome Pleural Malin, Diseases [C] - Cancer [C04]
 
 
2019-002721-30: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Ongoing
2
118
Europe
Yervoy, Opdivo, UV1, Leukine, BMS-936558, Infusion, Powder and solvent for solution for injection, Yervoy (ipilimumab), Opdivo (nivolumab), Leukine
Oslo University Hospital, BMS Pharmaceuticals Ltd, Ultimovacs
Malignant pleural mesothelioma (MPM), Malignant pleural mesothelioma (MPM), Diseases [C] - Cancer [C04]
 
 
NCT03502746: Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Terminated
2
34
US
Nivolumab, Opdivo, Ramucirumab, Cyramza
Arkadiusz Z. Dudek, MD, HealthPartners Institute Regions Cancer Care Center, Eli Lilly and Company, Bristol-Myers Squibb
Mesothelioma, Malignant
05/22
11/23
NCT04013334: MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Active, not recruiting
2
12
US
MTG201, Ad-SGE-REIC/Dkk-3, Nivolumab Injection [Opdivo], Opdivo
Momotaro-Gene Inc., Baylor College of Medicine, Synteract, Inc.
Malignant Pleural Mesothelioma
12/22
01/23
NCT05041062: A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Completed
2
2
US
Nivolumab, Opdivo, ONO-4538, BMS-936558, MDX1106, Ipilimumab, Yervoy
University of Chicago
Mesothelioma, Peritoneal Mesothelioma
04/23
04/23
NIPU, NCT04300244: Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Hourglass Jul 2022 - Dec 2022 : Top-line data from NIPU trial in combination with UV1 and Yervoy for malignant mesothelioma
Active, not recruiting
2
118
Europe, RoW
UV1 vaccine + leukine, ipilimumab, Yervoy, nivolumab, Opdivo
Åslaug Helland, Oslo University Hospital, Ultimovacs ASA, Bristol-Myers Squibb
Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma, Mesothelioma; Lung, Mesothelioma; Pleura, Mesotheliomas Pleural
03/25
03/27
NCT05429866: Immunological Variables Associated to ICI Toxicity in Cancer Patients

Recruiting
2
441
Europe
Checkpoint Blockade, Immune, Ipililumab, Nivolumab, Pembrozilumab, atezolizumab, avelumab, durvalumab, Cemiplimab
Jules Bordet Institute
Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Mesothelioma, Malignant, Bladder Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, MSI-H Colorectal Cancer
06/24
12/24
ANTARES, NCT06638931: Agnostic Therapy in Rare Solid Tumors

Recruiting
2
28
RoW
Nivolumab
Instituto do Cancer do Estado de São Paulo, Financiadora de Estudos e Projetos
Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma, Secretory Carcinoma of Breast, Anal Neoplasms, Metaplastic Breast Carcinoma, Translocation Renal Cell Carcinoma, Carcinosarcoma, Small Intestine Neoplasms, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Adenoid Cystic Carcinoma, Mesothelioma, Neuroblastoma, Adrenal Gland Neoplasms, Penile Neoplasms, Apocrine Carcinoma, Fibrosarcoma, Cancer of Unknown Primary, Hemangioblastoma, Thyroid Neoplasms, Hepatoblastoma, Fallopian Tube Neoplasms, Leiomyosarcoma, Vaginal Neoplasms, Neurofibrosarcoma, Gallbladder Neoplasms, Osteosarcoma, Biliary Tract Neoplasms, Clear Cell Endometrial Cancer, Yolk Sac Tumor, Vulvar Neoplasms, Kaposi Sarcoma, Ovarian Epithelial Cancer, Soft Tissue Sarcoma, Urethral Neoplasms, Granulosa Cell Tumor, Primitive Neuroectodermal Tumor, Neuroendocrine Tumors, Trophoblastic Tumor
07/26
05/28
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NICITA, NCT04177953: Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Active, not recruiting
2
92
Europe
Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb
Pleural Mesothelioma Malignant
12/24
01/25
A082101, NCT05647265: Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Recruiting
2
26
US
Nivolumab, 946414-94-4, BMS-936558, CMAB819, MDX-1106, NIVO, NIVOLUMAB, Nivolumab, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Ipilimumab, 477202-00-9, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, IPILIMUMAB, ipilimumab, Ipilimumab Biosimilar CS1002, MDX-010, MDX-010, MDX-CTLA4, Yervoy, Surgical Procedure, Computed Tomography, CAT, CAT Scan,, Magnetic Resonance Imaging, MRI, Positron Emission Tomography, Medical Imaging, PET, Pet Scan
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
12/24
12/24
NCT03918252: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active, not recruiting
2
30
US
Nivolumab Injection, Optivo, Ipilimumab Injection, Yervoy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Mesothelioma
06/25
06/26
IMPALA, NCT04400539: The IMmunotherapy Pleural 5-ALA PDT

Recruiting
2
20
Europe
intrapleural photodynamic therapy with videothoracoscopy, Nivolumab Injection, adjuvant immunotherapy with anti-PD-1 Nivolumab antibodies
University Hospital, Lille, INSERM U1189 ONCOTHAI
Mesotheliomas Pleural, Malignant Pleural Mesothelioma
05/26
05/26
CheckMate 6DW, NCT05136677: A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Recruiting
2
100
RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb
Mesothelioma, Malignant
10/26
10/26
NCT03907852: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting
1/2
36
Canada, US
gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
TCR2 Therapeutics, Bristol-Myers Squibb
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
11/28
11/28
NCT06362369: A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy

Recruiting
1/2
126
US
Alintegimod, 7HP349, Ipilimumab, Yervoy, Nivolumab, Opdivo
7 Hills Pharma, LLC
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
12/27
12/28
NCT02637531: A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Checkmark From MARIO-1 trial in combination with IPI-549 for solid tumors
Nov 2020 - Nov 2020: From MARIO-1 trial in combination with IPI-549 for solid tumors
Checkmark From P1/1b trial in combination with IPI-549 for advanced solid tumors
Nov 2020 - Nov 2020: From P1/1b trial in combination with IPI-549 for advanced solid tumors
Checkmark Clinical & translational data from expansion cohorts of MARIO‑1 phase 1b study in combination with Opdivo
More
Active, not recruiting
1
219
US
IPI-549 (eganelisib), Nivolumab, OPDIVO
Infinity Pharmaceuticals, Inc.
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
01/22
12/22
NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Active, not recruiting
1
10
US
Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF
Memorial Sloan Kettering Cancer Center
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
07/25
07/25
NCT04162015: A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Active, not recruiting
1
22
US
Nivolumab, Pemetrexed, Cisplatin or Carboplatin
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Malignant Pleural Mesothelioma
11/25
11/25
NCT05298592: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Completed
1
77
Europe, Japan, US, RoW
BMS-986406, Nivolumab, BMS-936558, Opdivo, Carboplatin, Pemetrexed, Paclitaxel
Bristol-Myers Squibb
Advanced Cancer
08/24
08/24
MT-8421-001, NCT06034860: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Terminated
1
15
US
MT-8421, Nivolumab
Molecular Templates, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
10/24
10/24
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab

Active, not recruiting
N/A
200
Europe
Data collection
Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
04/25
04/25
CA209-6AF, NCT05324436: A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Recruiting
N/A
50
Japan
Bristol-Myers Squibb
Mesothelioma, Malignant
09/24
03/25

Download Options